BioSpace News Archive

IND for KP879 Expected to be Filed Before Year-End 2020; New Prodrug CandidateAdded to Pipeline,Targeting Rare CNS Disease, Idiopathic Hypersomnia (IH)

IntelGenx Technologies Corp. announced that the Company’s board of directors granted stock options to acquire a total of 1,365,000 common shares under the 2016 Stock Option Plan.

Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian gland dysfunction (MGD) and related eye diseases, today announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference.

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the biopharmaceutical company AstraZeneca has licensed ION455, an investigational antisense medicine being developed as a potential treatment for nonalcoholic steatohepatitis (NASH)

Today, the U.S. Food and Drug Administration approved Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria type 1 (PH1), a rare genetic disorder.

ViviGen® Cellular Bone Matrix is associated with significantly lower hospital costs compared to recombinant human bone morphogenetic protein-2 (rhBMP-2), according to an analysis of more than 16,000 U.S. lumbar fusions procedures.

Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following virtual investor conferences in December:

HF Enterprises Inc., a diversified holding company principally engaged through its subsidiaries in property development, digital transformation technology and biohealth activities, announced the pricing of its initial public offering of 2,160,000 shares of its common stock at a public offering price of $7.00 per share for gross proceeds of $15,120,000 before deducting offering expenses.

iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that management will present at the Piper Sandler 32nd Annual Healthcare Conference, taking place December 1 – 3, 2020.

Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer has participated in a fireside chat presentation and will host investor meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held on December 1-3, 2020.